德英生物科技
詢價車

Sustainable Value

Company Introduction

DEYIN was founded in August 2002, and in October of the same year, it passed the review of the Ministry of Science and Technology and was approved to establish a plant in the Southern Taiwan Science Park. New drug development is a cross-disciplinary mission. The team’s expertise covers biochemistry, physiology, molecular biology, pharmacology, horticulture, animal testing, and quality analysis. The team is led by Professor Kuo Kuo-Hua, who has 40 years of drug development experience.

The company focuses on botanical new drug development. Its current paid-in capital is NT$589,996,000, specializing in developing natural plants into botanical drugs that meet Western-medicine standards, targeting difficult-to-treat diseases such as cancer, liver, gallbladder, and kidney disorders.

R&D Capabilities

The company’s “Plant Activity and Mechanism Research Center” has passed the review of the National Science Council, demonstrating research capabilities on par with academic institutions, and has completed numerous government-funded and industry-academia collaboration projects.

  • New drug SR-T100 Gel: Completed Phase III clinical trials and received U.S. FDA approval for Phase II trials. Targets actinic keratosis and condyloma acuminatum.
  • A new injectable drug is under development for treating malignant ascites in terminal cancer patients.
  • Silymarin new drug development has achieved the world’s highest pharmacopeia dissolution rate, breaking through limitations in treating liver, gallbladder, and kidney diseases.

Facilities and Mass Production

DEYIN has established government-certified facilities, including a plant extraction facility, food factory, cosmetics factory, and PIC/S GMP pharmaceutical plant. The company possesses complete vertical integration, from raw material cultivation to quality analysis and production.

Its product lines include natural plant-based foods, plant-based functional cosmetics, pharmaceuticals, and clinical trial drugs.

Corporate Governance & Sustainability

On March 21, 2011, DEYIN was approved for OTC listing (Stock Code 4911) by the Taipei Exchange. The company adheres to ethical management, does not engage in reinvestment or bank borrowing, and all land and facilities are self-owned.

In recent years, the company has actively implemented ESG, promoting corporate governance, social responsibility, and environmental protection, dedicated to:

  • Creating a safe and friendly work environment
  • Complying with government regulations and implementing improvement measures
  • Establishing a sustainable business model that benefits society and the environment

Conclusion

With its botanical new drug technologies and complete production capabilities, DEYIN has become a key leader in Taiwan’s botanical new drug industry. The company will continue developing innovative drugs, building an international brand, and making its mark in the global biopharmaceutical market.

Sustainability Organization

Main Department Business Scope
Audit Office 1. Inspect and evaluate the internal control system, and provide analysis and improvement suggestions.
2. Facilitate effective management control and operational efficiency at reasonable costs.
3. Establish, revise, and implement internal audit procedures.
4. Formulate annual audit plans and track improvement actions.
5. Conduct regular and irregular audits and issue audit reports.
6. Prepare and execute self-inspection plans.
7. Budget supervision and tasks assigned by supervisors.
General Manager's Office 1. Corporate strategy development and project planning.
2. Business goal planning and tracking.
3. Assist the General Manager with business affairs.
4. Supervise operational procedures and key document management.
5. Review annual budgets and operating reports.
6. Promote project initiatives.
7. Handle stock affairs and maintain investor relations.
R&D Department 1. New technology and product development.
2. Execution of research projects.
3. Technology transfer and establishment of pilot production conditions.
4. Laboratory quality and process monitoring.
Quality Control Department 1. Process and yield improvement.
2. Quality target management and monitoring.
3. Finished product quality and flow control.
Manufacturing Department 1. Raw material requirement assessment.
2. Production scheduling control.
3. Warehouse management.
4. Production quality and safety maintenance.
Marketing Department 1. Marketing strategy and market development.
2. Product sales and after-sales service.
3. Brand image and media planning.
4. Exhibition and international promotion activities.
5. Performance analysis and operational planning.
Administration Department 1. Administrative and personnel management.
2. Procurement and general affairs management.
3. Training and project support.
4. Digitalization initiatives and regulatory filings.
Finance Department 1. Budget preparation and control.
2. Cash flow management and accounting.
3. Cost calculation and tax filing.
4. Required reports and submissions to regulatory authorities.